ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Attachment
| Source: Oculis Holding AG
ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Attachment
ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market...
Read MoreBreakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. aloneMultiple milestones...
Read More